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Abstract 
Objectives: UK guidelines advise that patients with pulmonary MDR-TB are isolated in 
hospital until sputum cultures are negative (culture-conversion), typically after 42 days of 
incubation with no growth. MDR-TB patients may be isolated at least 42 days longer than is 
necessary for public safety, which has major implications for patients and hospitals. Our 
objective was to determine whether analysis of Time-To-Detection (TTD) in liquid culture 
could predict the earliest safe discharge date of MDR-TB patients. 
Patients and methods: 15 pulmonary MDR-TB patients were identified retrospectively from 
the London TB Register and hospital records. We performed linear regression of TTD against 
days elapsed between admission and sample date. If the regression line crossed the observed 
culture-conversion date at TTD=42 days, the data were deemed to give ‘precise prediction’ of 
the earliest safe discharge date. 
Results: Median length-of-stay was 91 days (IQR 79-131 days). Culture-conversion occurred 
at a median of 59 days (IQR 46-86 days). Twelve patients were hospitalised beyond culture-
conversion, with a median overstay of 52 days (IQR 35-68 days). TTD tended to lengthen 
until culture-conversion and, for half of the patients (7/15, 47%), linear regression of TTD 
against time from admission gave a good fit to the data (r2≥0.6) and supported precise 
prediction. However, data from the remaining patients showed considerable variation, and 
linear regression did not support prediction of safe discharge. 
Conclusion: TTD data from these pulmonary MDR-TB patients did not support a simple 
clinical prediction tool, but our analysis was limited by the small size of our sample. 
 
 
Introduction 
In the UK, 1.4% of new and 5.7% of previously treated TB cases are estimated to be multi-
drug resistant, i.e. resistant to rifampicin and isoniazid, representing approximately 80 MDR-
TB patients per year.1,2  In the absence of direct measures of infectivity, sputum smear and 
culture status are used as surrogate markers of infectivity. UK guidelines advise that patients 
with pulmonary MDR-TB are isolated in hospital until all sputum cultures taken within one 
month are negative (culture-conversion).3,4 A sample is typically considered culture-negative 
after 42 days of incubation with no growth. It therefore follows that pulmonary MDR-TB 
patients are isolated at least 42 days longer than is necessary for public safety, which has 
major implications for patients and hospitals. 
 
Though “vital” staining methods and molecular indicators of viable bacillary burden are 
under development, e.g. fluorescein diacetate vital staining,5 RT-PCR of selected mRNA,6 
16S rRNA,7 and pre-rRNA responses to stimulation,8 none have yet superseded 
microbiological culture methods in guiding decisions on infectivity and isolation.9 Time-To-
Detection (TTD) in liquid medium is used as an endpoint in MDR-TB drug efficacy 
studies,10,11 and may be a stronger predictor of infectivity than smear positivity.12 We sought 
to determine whether we could predict, from the analysis of TTD in liquid culture, the earliest 
possible safe discharge date of pulmonary MDR-TB patients from our unit. 
 
Methods 
We identified retrospectively patients from the London TB Register with culture-positive 
pulmonary TB confirmed as phenotypically resistant to rifampicin and isoniazid, treated at 
Northwick Park Hospital (NPH) 2003 - 2014. Sputum samples were collected weekly 
throughout admission, and processed in NPH’s microbiology laboratory. Standard Operating 
Procedures included sodium hydroxide decontamination and incubation in the BacT/Alert 3D 
Microbial Detection System (bioMérieux, France). Data on patient demographics, phenotypic 
drug susceptibilities, dates of admission and discharge, and sputum culture TTD throughout 
treatment were extracted from electronic medical records. We excluded extrapulmonary TB, 
and those who were culture-positive at less than 3 time points. Treatment regimens were 
individualized and adjusted during treatment. 
 
The earliest possible date of safe discharge coincides with the ‘culture-conversion date’, i.e. 
the date of the first sample which is culture negative after 42 days, and for which no sample 
dated within 30 days of the first sample becomes culture positive (after 42 days). Positive 
cultures with contaminants, positive cultures without clear TTD, and reloaded samples were 
excluded. We calculated Length of Stay as date of discharge minus date of admission, and 
“Overstay” as date of discharge minus date of culture-conversion. For each patients, we 
performed linear regression of TTD (days) against days elapsed between admission (or date 
of first sample, if this taken before admission) and date of sample. Adjusted r2 values were 
inspected as a measure of goodness-of-fit of the data. If the regression line crossed the 
observed culture-conversion date at TTD=42 days, the data were deemed to support ‘precise 
prediction’ of the earliest safe discharge date. Data were analysed using Stata (StataCorp. 
2015. Stata Statistical Software: Release 14. College Station, TX: StataCorp LP). 
 
Results 
We identified 52 MDR-TB patients, of whom 32 were pulmonary cases and 15 met all 
criteria [Supplementary Figure 1]. All 15 were smear positive before treatment, with smear 
grade from “scanty” to “large numbers”. Nine were male (7 HIV negative, 1 HIV positive, 1 
HIV status unknown), six female (all HIV negative). The age range was 13-59 years, median 
34 years old. Among these 15 patients, Length of Stay was 74-178 days (median 91 days, 
IQR 79-131 days); culture-conversion occurred at 28-112 days (median 59 days, IQR 46-86 
days). Twelve remained in-patients beyond culture-conversion, and Overstay ranged from 
16-122 days (median 52 days, IQR 35-68 days). [Supplementary Table 1].  
 
Resistance to other first-line and second-line agents varied [Supplementary Figure 2; 
Supplementary Table 1]. Initial specimen TTDs ranged from 7 to 29 days. Initial TTD did not 
predict time to culture-conversion, and TTD tended to lengthen until culture-conversion. For 
the majority of patients, linear regression of TTD against time from admission gave a good 
fit. Each plot of TTD vs treatment had different intercept, gradient (0.06-1.29 days-to-
detection/day of admission), and goodness-of-fit (r2 = 0.05-0.90). [Figure 1]. Closer fit 
(higher r2) appeared to be more common with shorter initial TTD, particularly if TTD was 
<12days. 
 
Half of the TTD regression lines (7/15, 47%) crossed observed culture-conversion dates, i.e. 
“precise prediction” [Figure 1: patients B, D, L, O, R, U, V]. Precise prediction of culture-
conversion did not appear to be associated with sputum smear grade or patient age, sex or 
HIV status. The seven plots with precise prediction were amongst those with better fit of 
linear regression (r2≥0.6), and represented mycobacterial isolates without additional 
resistance to 2nd line injectables, quinolones, or prothionamide. Only 1/7 was resistant to 
pyrazinamide, compared with 5/8 of those without precise prediction.  
 
Discussion 
Our MDR-TB patients had a median Length of Stay of 91 days, of which one third was 
probably unnecessary, because culture-conversion occurred at a median of 59 days. Although 
TTD tended to lengthen on treatment, and linear regression allowed “precise prediction” in 7 
of 15 patients, the goodness of fit of linearity and the rate of change of TTD varied markedly 
between patients. This variation may be due to host factors (immune response, nutritional 
status, pharmacokinetics, and anatomy, including the behaviour of cavities), bacterial factors 
(drug susceptibilities at baseline and during treatment) and treatment factors (individualized 
regimens, specific drugs, changes to regimens and treatment interruptions). Precise prediction 
did not appear to be associated with baseline characteristics (age, sex, sputum smear grade, 
HIV status), but additional drug resistances were more common amongst patients whose TTD 
plots did not accurately predict culture-conversion. Further research is needed to identify the 
characteristics of MDR-TB patients for whom TTD has prognostic utility, e.g. by fitting a 
single predictive model to combined data from a larger sample of patients, including baseline 
and treatment factors. 
 
We conclude that conventional bacteriological methods could not have been used to predict 
date of culture-conversion to facilitate earlier discharge for all of our pulmonary MDR-TB 
patients. However, our study was limited by the small sample size and, for the subgroup of 
patients for whom the method accurately predicted culture-conversion, TTD could serve as a 
useful prognostic tool and aid to discharge planning. This would be a relatively accessible 
methodology for countries where molecular methods are not readily available. 
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Figure legends: 
Figure 1: Plots of Time-to-Detection (TTD) against time elapsed between admission and 
date of sample. 
 
Supplementary data: 
Supplementary Figure 1: Patient inclusion/exclusion flowchart. 
Supplementary Figure 2: Summary chart of phenotypic susceptibilities and resistances to 
tested agents. 
Supplementary Table 1: Patient age, sex, HIV status and drug susceptibilities. 
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